News

Joint Study to Commence on the Supply of Ethylene Derivatives derived from Bio-based Raw Materials

• Investor Relations

Consolidated Financial Results, Q1-FY2021 

• Investor Relations

Notice of Revisions to Earnings Forecasts and Dividends Forecasts for the Fiscal Year ending March 31, 2022

• Investor Relations

Summary of Consolidated Financial Results For the First Quarter of the Fiscal Year Ending March 31, 2022

Establishment of a Green Innovation Department to achieve carbon neutrality by 2050

Nippon Shokubai Obtains ISCC PLUS for Bio-based Superabsorbent Polymers -To Contribute to the Reduction of the Environmental Impact of Disposable Diapers-

• Investor Relations

Notice of Resolutions Adopted at The 109th Ordinary General Meeting of Shareholders

• Investor Relations

Notice of resolutions adopted at the 109th ordinary general meeting of shareholders

Nippon Shokubai Receives the Technology Award from the Catalyst Manufacturers Association, Japan -Identified an exhaust-gas detoxification mechanism of De-NOx catalyst-

Clinical Research on Knee Osteoarthritis using MicoCell 3D Cell Culture Vessel -Patients were Injected with Cell Aggregates at our Collaborative Research Clinic-

• Investor Relations

Convocation Notice of The 109th Ordinary General Meeting of Shareholders

• Investor Relations

Convocation notice of the 109th ordinary general meeting of shareholders

Price Increase for Maleic Anhydride, Succinic Acid and Disodium Succinate “SS50”

• Investor Relations

Financial Results Briefing Material, Q4-FY2020

Developing Novel electron injection material contributing to lower power consumption, longer operating lifetime and reduce cost of OLED

• Investor Relations

Consolidated Financial Results, Q4-FY2020 

• Investor Relations

Summary of Consolidated Financial Results For the Fiscal Year Ended March 31, 2021

• Investor Relations

Views and Policy, etc. Regarding Investment Unit Reduction

Establishment of the Nippon Shokubai Group Long-Term Vision, “TechnoAmenity for the future”

• Investor Relations

Notice of Revisions to Earnings Forecasts and of Recording of Impairment Losses (Consolidated Basis) and Loss on Valuation of Shares of Subsidiaries and Affiliates (Non-Consolidated Basis) for the Fiscal Year ended March 31, 2021